Register here
Christian Klingbeil
Partner, Deal Advisory - Valuation
KPMG AG Wirtschaftsprüfungsgesellschaft
+49 89 9282 1284 Christian
Klingbeil
Phone number
Current Issue:
The new edition of our newsletter on transactions in the global life sciences industry glances back at the significant deals that took place in Q1 2025 and provides further insights on the industry’s market trends.
- M&A activity: Q1 2025 noted a decline in overall M&A activity within the Life Sciences industry compared to Q1 2024, both in value and volume. However, the period was marked by several high-value strategic transactions, reflecting the focused approach taken by investors.
- Market sentiment: Despite prevailing geopolitical uncertainties and potential trade conflicts, particularly affecting the US and EU markets, investors maintained a stance of cautious optimism.
- M&A focus: Some companies strategically acquired firms with well-differentiated, late-stage assets to boost their pipelines and market competitiveness, especially in areas such as oncology, immunology, and cardiovascular diseases.
- M&A driver: Strong financial resources, critical pipeline needs due to looming patent cliffs, and generally favorable regulatory conditions, collectively fostering a robust environment for continued M&A activity.
